

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Pacific Blue(TM) anti-human CD3

RRID:AB_10551436

Type: Antibody

Proper Citation

BioLegend Cat# 300330, RRID:AB_10551436

Antibody Information

URL: http://antibodyregistry.org/AB_10551436

Proper Citation: BioLegend Cat# 300330, RRID:AB_10551436

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_10551436

Vendor: BioLegend

Catalog Number: 300330

Alternative Catalog Numbers: 300329

Record Creation Time: 20250820T004641+0000

Record Last Update: 20250820T091050+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-human CD3.

No alerts have been found for Pacific Blue(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Li YR, et al. (2026) Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. Signal transduction and targeted therapy, 11(1).

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer cell, 43(3), 503.

Li YR, et al. (2025) Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nature protocols, 20(5), 1352.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Parry EM, et al. (2023) ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer cell, 41(10), 1803.

Chikata T, et al. (2023) HIV-1 protective epitope-specific CD8+ T cells in HIV-1-exposed seronegative individuals. iScience, 26(11), 108089.

Kashima Y, et al. (2022) Intensive single-cell analysis reveals immune-cell diversity among healthy individuals. Life science alliance, 5(7).

Bellini N, et al. (2022) MiRNA-103 downmodulates CCR5 expression reducing human immunodeficiency virus type-1 entry and impacting latency establishment in CD4+ T cells. iScience, 25(10), 105234.

Kim C, et al. (2018) Activation of miR-21-Regulated Pathways in Immune Aging Selects against Signatures Characteristic of Memory T Cells. Cell reports, 25(8), 2148.